Barclays’s Puma Biotechnology PBYI Stock Holding History

Barclays’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,000	Closed	-$194K	–	7168
2019 Q1	$194K	Sell	5,000 -4,600	-48%	-$140K	﹤0.01%	4850
2018 Q4	$195K	Buy	+9,600	New	+$288K	﹤0.01%	4594
2018 Q3	–	Sell	-200	Closed	-$12K	–	7325
2018 Q2	$12K	Sell	200 -2,500	-93%	-$145K	﹤0.01%	6466
2018 Q1	$184K	Sell	2,700 -56,900	-95%	-$4.26M	﹤0.01%	4904
2017 Q4	$5.89M	Buy	59,600 +29,700	+99%	+$3.32M	﹤0.01%	1538
2017 Q3	$3.58M	Sell	29,900 -22,100	-43%	-$2.06M	﹤0.01%	1800
2017 Q2	$4.54M	Buy	52,000 +50,800	+4,233%	+$2.84M	﹤0.01%	1543
2017 Q1	$45K	Buy	+1,200	New	+$43.8K	﹤0.01%	5397
2015 Q2	–	Sell	-8,900	Closed	-$2.1M	–	7148
2015 Q1	$2.1M	Sell	8,900 -6,500	-42%	-$1.39M	﹤0.01%	2268
2014 Q4	$2.91M	Sell	15,400 -45,900	-75%	-$10.2M	﹤0.01%	2181
2014 Q3	$14.6M	Buy	+61,300	New	+$12.6M	0.01%	915

Other funds holding PBYI

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Ritholtz Wealth Management New York $6.96B AUM 24% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Barclays's PBYI Position: Q3 2026 in Review

Barclays increased its Puma Biotechnology (PBYI) stake by 97% in Q3 2026, buying an estimated $95.9K and bringing the position to 22,098 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #3901.

Barclays first reported a position in PBYI in Q2 2013 and has held it in 53 quarters since. The position peaked at $22.5M in Q3 2017. 77 funds tracked by Wall St. Rank hold PBYI as of Q3 2026.

Barclays held 22,098 shares of Puma Biotechnology worth $219K as of Q3 2026.
Barclays bought 10,896 Puma Biotechnology shares in Q3 2026, an estimated $95.9K.
Puma Biotechnology made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3901 holding.
Barclays first reported a position in Puma Biotechnology in Q2 2013 and has held it in 53 quarters since.
Barclays's Puma Biotechnology position peaked at $22.5M in Q3 2017.
77 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.